IFIH1 and dermatomyositis: Earlier studies investigating the clinical manifestations of anti-MDA5 positive DM have demonstrated a higher risk of ILD in patients with positive anti-MDA5 antibody compared to those with negative antibodies or other myositis antibodies [42–51].